AbbVie Inc (ABBV) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Total Cash From Operating Activities Chart for AbbVie Inc
AbbVie Inc (ABBV) operating cash flow for FY2025 was USD 19.0B, a 1.2% change from FY2024. AbbVie Inc's operating cash flow grew from USD 5.4B in 2009 to USD 19.0B in 2025 (254.6% over 16 years). Operating cash flow compound annual growth rate: 5-year CAGR of 1.6%, 10-year CAGR of 9.7%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $430.95B
- Implied Share Price
- $243.87
- Enterprise Value
- $506.83B
- Revenue (TTM)
- $64.39B
- EBITDA
- $30.76B
- Profit Margin
- 9.80%
- Trailing P/E
- 69.48
- Forward P/E
- 17.79
- Price/Book (MRQ)
- 50.46
- Price/Sales (TTM)
- 6.69
- EV/EBITDA
- 44.16
- EV/Revenue
- 7.87
- Dividend Yield
- 2.77%
- Book Value
- $-3.36
- Free Cash Flow (FY2025)
- $17.82B
- Free Cash Flow Yield
- 4.13%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.